Genotype-guided Targeted Agents Plus EZH2i for Primary Refractory PTCL

Inclusion Criteria:

* Age ≥ 18 years, male or female.
* Patients with a histopathologically confirmed diagnosis of peripheral T-cell lymphoma (PTCL) based on 2016 WHO classification
* Previously treated with 3 or 6 cycles of a CHOP-like regimen as first-line therapy and considered primary refractory. Patients with anaplastic large cell lymphoma (ALCL) must have adequately received brentuximab vedotin (BV) as part of their first-line treatment.
* Tumor tissue genotyping performed and results available prior to enrollment.
* ECOG 0, 1, or 2.
* Life expectancy greater than 3 months.
* Adequate organ function
* Contraception during study
* Informed consented

Exclusion Criteria:

* Has a prior malignancy other than the malignancies under study within 3 years without relieve
* Primary CNS lymphoma
* Known hypersensitivity to any study drug.
* Pregnant or lactation
* Active infection.
* Diseases and medical history:

  1. Requires continuous treatment with strong or moderate CYP3A inhibitors or CYP3A inducers
  2. Has multiple factors affecting oral medication administration (e.g., inability to swallow, chronic diarrhea, intestinal obstruction, etc.);
  3. Has a history of psychoactive substance abuse that cannot be discontinued
  4. Has any severe and/or uncontrolled disease.
* Uncontrollable autoimmune disease,
* Not able to comply to the protocol for mental or other unknown reasons
* Any other condition that, in the investigator's judgment, makes the patient unsuitable for study participation.